PTC (PTC) is drawing investor attention after a recent stretch of weaker share performance, with the stock showing declines ...

PTC (NASDAQ: PTC) will release its fiscal 2026 first quarter and on Wednesday, February 4 th after the stock market closes.

Conference draws participants from more than 60 countries; demand for leadership programs reaches capacity From sold ...

PTC Therapeutics (PTCT) beats 2025 revenue guidance, details Evrysdi royalties and Sephience growth, and sets 2026 outlook.

PTC Therapeutics is keeping its regulatory teams busy. In its third-quarter results, the biotech reported pushback against its plans to seek approval for two molecules based on existing data—and saw ...

Founded in 1985, the Boston, Massachusetts-based PTC Inc. (PTC) provides software solutions and services globally that aid ...

PTC Therapeutics, Inc. (NASDAQ: PTCT) today provided an update on the Company's progress and its outlook for 2026. Matthew B. Klein, M.D., Chief Executive Officer of PTC, will discuss these updates at ...

Shares of PTC Inc. PTC shed 1.18% to $171.52 Friday, on what proved to be an all-around great trading session for the stock ...

PTC Therapeutics faces pivotal FDA decisions for Translarna and Vatiquinone, with outcomes uncertain while both approvals are potentially transformative for long-term revenues. The Novartis ...